CD44 and acute myeloid leukemia: Nevertheless, driver mutations in isocitrate dehydrogenase 1 or 2 (IDH1, IDH2), nucleophosmin (NPM1), FLT3, as well as splice variants in other genes (e.g., CD44) exhibit neoepitopes potentially suitable as tumor-specific antigens for the purpose of CAR-modified IEC therapy in AML [136].